Senti Biosciences, Inc. Overview
Pro stress-test →Senti Biosciences is a clinical stage biotechnology company developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Strategic Profile
Pro stress-test →The company's platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases. Its core technologies include the SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.
Competitive Landscape
Pro stress-test →Competitors in the cell therapy and synthetic biology space include companies such as Clearmind Medicine, Seres Therapeutics, FibroBiologics, and other emerging biotechs. Senti differentiates through its proprietary gene circuit platform that enables logic-gated control of therapeutic cells, providing potential advantages in safety and efficacy.
Industry Context
Senti Biosciences, Inc. operates in Biotechnology - Cell and Gene Therapies.
Key facts
Headquarters: South San Francisco, California · Market cap: $24.82M